Abstract:
Provided is a 2-substituted aminoalkylenyloxy-3-substituted phenylethynyl quinoxaline derivative, capable of suppressing expression of a WNT gene and proliferation of a cancer cell. A 2-substituted aminoalkylenyloxy-3-substituted phenylethynyl quinoxaline derivative is represented by the formula 1. In the formula 1, Y and Z is independently a hydrogen atom, halogen atom, C1-C8 alkyl group, or a C1-C8 alkoxy group; and R shows -X-Het. or -X-NR1R2, in which X is a C1-C8 alkylene group or a C2-C8 alkylene oxyalkylene group, and R1 and R2 is independently a hydrogen atom, C1-C8 alkyl group, or a pentagon or heptagon hetero group in which a hetero atom selected from another nitrogen atom or an oxygen atom with the nitrogen boned to the R1 and R2 is included.
Abstract:
A pharmaceutical composition for inhibiting oxidative stress is provided to treat Alzheimer's diseases and cerebral apoplexy by using a 2-methyl-2'-hydroxymethyl-6-amidobenzopyran derivative and its salts. A pharmaceutical composition for inhibiting oxidative stress comprises a 2-methyl-2'-hydroxymethyl-6-amidobenzopyran derivative represented by the formula 1. A method for manufacturing the 2-methyl-2'-hydroxymethyl-6-amidobenzopyran derivative consists of the following steps of manufacturing a 6-amino benzopyran derivative represented by the formula 3 by reducing a 6-nitrobenzopyran derivative represented by the formula 2 with 1.0-3.0 mole equivalent of reductant.
Abstract:
본 발명은 신규 6-알킬아미노-2-메틸-2'-( N- 메틸치환술폰아미도)메틸-2 H- 1-벤조피란 유도체와, 조합화학 합성기술 중 하나인 평형합성법을 이용하여 상기한 신규 화합물을 고효율로 합성하는 방법, 그리고 상기한 신규 화합물이 우수한 5-라이폭시게네이즈(5-LO) 저해효과를 나타내므로 관련 류코트리엔(LTA4, B4, C4, D4)의 활성으로 유발되는 염증질환, 류마티스성 관절염, 대장염(Colitis), 천식, 건선 등의 예방 및 치료제로 사용하는 용도에 관한 것이다. 조합화학 합성, 평형 합성, 5-라이폭시게네이즈, 항염증 질환 치료제, 약리학적 효능, 2'-술폰아미도메틸벤조피란, 유사약물 라이브러리
Abstract:
A novel 6-alkylamino-2-methyl-2-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative is provided to show excellent 5-lipoxygenase(5-LO) inhibition effect, thereby being used for preventing and treating inflammatory diseases induced by related leukotrien(LTA4, B4, C4, D4), rheumatoid arthritis, colitis, asthma, and psoriasis. The 6-alkylamino-2-methyl-2-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative is represented by the formula(1), where R^1 is C1-10 alkyl; phenyl; phenyl substituted by a substituent selected from the group consisting of C1-6 alkyl, C1-6 acyloxy, C1-10 alkoxyalkyl, and C1-10 dialkoxyalkyl; benzyl; benzyl substituted by a substituent selected from the group consisting of halogen, nitro, cyano, hydroxy, C1-6 alkyl and C1-6 alkoxy; phenethyl; pyridyl methyl; thiophene methyl; or thiophene methyl substituted by C1-6 alkyl, each R^2 and R^3 is independently H; or C1-6 alkyl, and R^4 is C1-10 alkyl; phenyl; phenyl substituted by a substituent selected from the group consisting of C1-6 alkyl and C1-6 alkoxy; or thiophene. The anti-inflammatory agent comprises the 6-alkylamino-2-methyl-2-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative represented by the formula(1).
Abstract:
본 발명은 RTK(Receptor Tyrosine Kinase; 수용체 티로신 효소) 저해활성이 우수한 다음 화학식 1로 표시되는 6-알킬아미노-2,2'-이중치환-벤조피란 유도체와 이의 이성질체, 및 약제학적으로 허용 가능한 이의 염을 항암제로서 사용하는 용도에 관한 것이다.
상기 화학식 1에서, R 1 , R 2 , R 3 , R 4 , n은 각각 발명의 상세한 설명에서 정의한 바와 같다. 아미노벤조피란, 수용체 티로신 효소, 상피세포, 항암제, RTK